Yuuwa Capital
Yuuwa Capital is a Perth-based venture capital firm specialising in early-stage life sciences commercialisation. Founded in 2009, it manages a $40M fund backed by the Australian Federal Government's IIF program, providing capital and board-level expertise to early-stage life sciences ventures.
- Company typePrivate
- Founded2009
- HeadquartersPerth, Australia
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Yuuwa Capital does
Yuuwa Capital is a specialist early-stage life sciences commercialisation and investment firm headquartered in Perth, Western Australia, founded in 2009. The firm was originally established as the manager of a $40 million venture capital fund with capital from the Australian Federal Government's Innovation Investment Fund (IIF) program and private investors. Its stated function is to identify new projects, help founders and management teams start and scale companies in the life sciences sector, and connect specialist early-stage investors to high-quality life sciences ventures. There are no proprietary technology products or services — the "product" is the fund vehicle and the firm's operational support to portfolio companies.
Operationally, Yuuwa provides both capital and hands-on commercialisation expertise: direct equity investment, board representation, and ongoing portfolio support spanning concept-to-commercialisation activities. The team is led by co-founders Liddy McCall and James Williams, with documented track records including the founding of iCeutica Inc (acquired in 2011), co-founding and chairing ASX-listed Dimerix Limited (DXB), involvement in five FDA approved drugs and devices, board roles at AdAlta Limited (ASX:1AD), Argenica Ltd (ASX:AGN), Agworld Pty Ltd, Fitgenes Australia Limited, PolyActiva Pty Ltd, the Ear Science Institute of Australia, and the Perron Institute for Neurological and Translational Science. The disclosed portfolio comprises AdAlta, Agworld, Fitgenes, iCentana, Nexgen Plants, and PolyActiva.
Yuuwa's revenue model is that of a venture capital manager: management fees on the $40M fund and carried interest from realised exits and liquidity events on portfolio companies (both acquisitions and ASX listings). GTM is sales-led and network-driven, sourced through direct relationships in the Western Australian life sciences ecosystem and government channels established via the IIF partnership. The customer segment is narrow by definition — early-stage life sciences ventures seeking both capital and commercialisation support — making the firm's investment pipeline its primary sales channel.
Yuuwa Capital firmographics
Firmographics- Name
- Yuuwa Capital
- Legal name
- Yuuwa
- Website
- https://yuuwa.com.au
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Yuuwa Capital is a Perth-based venture capital firm specialising in early-stage life sciences commercialisation. Founded in 2009, it manages a $40M fund backed by the Australian Federal Government's IIF program, providing capital and board-level expertise to early-stage life sciences ventures.
- Ownership category
- akta.pro rank
Yuuwa Capital industry classification
Industry- Product category
- Venture Capital
- NAICS
- Portfolio Management and Investment Advice (523940), Other Financial Investment Activities (5239)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Emerging Manager / Seeding Platforms (Multi-Manager) (FSANAGAF)
Keywords
Where Yuuwa Capital is headquartered
LocationHeadquarters
- HQ city
- Perth
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
Yuuwa Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Others
Revenue model
- Investment Management Returns: Yuuwa generates returns through equity stakes in portfolio companies. The firm was initially established in 2009 as the manager of a $40 million venture capital fund with investment from the Australian Federal Government's Innovation Investment Fund (IIF) program and private investors. Returns are realised through exits of portfolio companies via acquisitions or IPOs.
Go-to-market motion1 record
Distribution channels1 record
Yuuwa Capital product offering
Product offeringCore offering
Yuuwa Capital is a specialist life sciences commercialisation and investment firm that manages a $40 million venture capital fund. The firm identifies new life sciences projects, helps founders and management start and scale their companies, and connects specialist early-stage investors with high-quality early-stage ventures. It provides both capital and direct hands-on commercialisation expertise, including board-level guidance, to portfolio companies in the life sciences sector.
Product overview
Yuuwa Capital is a specialist life sciences commercialisation and investment firm that provides both expertise and capital to identify and scale portfolio companies in the life sciences sector. The firm operates as a venture capital manager, connecting specialist early stage investors with high quality early stage ventures in life sciences. Yuuwa does not offer distinct technology products or services itself; its portfolio consists of investee companies including AdAlta, Agworld, Fitgenes, iCentana, Nexgen Plants, and PolyActiva.
Differentiator
Problem solved
Functional benefit
Products and services
- Yuuwa $40 Million Life Sciences Venture Capital Fund A venture capital fund that invests in early-stage life sciences ventures in Australia, providing both capital and hands-on commercialisation support, board representation, and ongoing guidance to portfolio companies. Targeted at early-stage life sciences startup founders and management teams.
- Life Sciences Commercialisation Support Hands-on commercialisation expertise and operational support provided directly by Yuuwa's co-founders to portfolio companies. Includes concept-to-commercialisation guidance, executive/board roles support, and management of all phases of building and scaling life sciences ventures. Targeted at early-stage life sciences companies that Yuuwa has invested in.
Quantifiable outcome
- Five FDA approved drugs and devices from team member James Williams
- +2 more outcomes
Companies that use Yuuwa Capital
Customer profileSegments1 record
Ideal customer profiles1 record
Yuuwa Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Yuuwa Capital partnerships and signals
Strategic signalScale indicators1 record
Recent moves4 records
Expansion highlights3 records
Yuuwa Capital competitors and assessment
Company assessmentBroad incumbents
- Square Peg Capital: Square Peg is a large Australian and Israeli venture capital firm. It is a broader incumbent in the Australian VC market, occasionally investing in health-tech adjacencies, but its primary focus is software/SaaS rather than life sciences.
- AirTree Ventures: AirTree is a prominent Australian venture capital firm with a broad tech mandate. Operates as a larger incumbent in the Australian VC ecosystem where Yuuwa also sources deals and competes for talent.
- Blackbird Ventures: Blackbird is one of Australia's largest venture capital firms. While not life-sciences-specialist, it participates in Australian tech and life sciences rounds and competes for talent and limited partners in the same Australian VC ecosystem as Yuuwa.
- Artesian Capital Management: Artesian is an Australian alternative asset manager with venture capital, private credit and cleantech mandates. Comparable to Yuuwa as an Australian-headquartered fund manager but operates at much larger scale and broader sector mandate.
Direct peers
- Main Sequence Ventures: Main Sequence Ventures is an Australian deep tech and science-backed venture firm (originating from the CSIRO Innovation Fund). It overlaps with Yuuwa in early-stage science-derived ventures and operates from a comparable Australian government-backed fund origin.
- BioScience Managers (now IQ Group): BioScience Managers was an Australian life sciences-focused investment manager; comparable to Yuuwa as a specialist life sciences manager raising capital from institutional and government sources and investing in Australian biomedical opportunities.
- Brandon Capital: Brandon Capital is an Australian life sciences-focused venture capital firm managing the Medical Research Commercialisation Fund (MRCF) and related vehicles. It is the closest direct peer to Yuuwa given its parallel mandate of investing in and commercialising Australian life sciences ventures, often alongside government and institutional capital.
- OneVentures: OneVentures is an Australian venture capital firm with dedicated healthcare and life sciences funds. It competes for similar early- and growth-stage Australian life sciences opportunities and operates a comparable fund-of-funds and direct investment model.
- Uniseed: Uniseed is a venture fund operating between Australian universities and early-stage commercialisation, with a strong focus on life sciences and deep tech. Comparable to Yuuwa as an early-stage investor providing hands-on commercialisation support to research-derived ventures in Australia.
Regional players
- CP Ventures: CP Ventures is an Australian deep tech and life sciences investor. Comparable to Yuuwa in early-stage science commercialisation, though operating from Sydney/Melbourne rather than Western Australia.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks2 records
Key highlights5 records
Customer concentration
Yuuwa Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
Yuuwa Capital leadership team
Management profileNumber of profiles
Profiles3 records
Yuuwa Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Yuuwa Capital M&A and investment
M&A and investmentM&A
Investments17 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Yuuwa Capital
What does Yuuwa Capital do?
Yuuwa Capital is a specialist life sciences commercialisation and investment firm that manages a $40 million venture capital fund. The firm identifies new life sciences projects, helps founders and management start and scale their companies, and connects specialist early-stage investors with high-quality early-stage ventures. It provides both capital and direct hands-on commercialisation expertise, including board-level guidance, to portfolio companies in the life sciences sector.
Is Yuuwa Capital a public or private company?
Yuuwa Capital is a private company. It is classified as unknown and is currently operating.
When was Yuuwa Capital founded?
Yuuwa Capital was founded in 2009. It employs 1 to 10 people.
Where is Yuuwa Capital based?
Yuuwa Capital is headquartered in Perth, Australia, in the Oceania region.
How does Yuuwa Capital make money?
One revenue line is on record: investment Management Returns.
Who are Yuuwa Capital's main competitors?
Broad incumbents on record are Square Peg Capital, AirTree Ventures, Blackbird Ventures and Artesian Capital Management. Direct peers are Main Sequence Ventures, BioScience Managers (now IQ Group), Brandon Capital, OneVentures and Uniseed. CP Ventures is listed as a regional player.
Does Yuuwa Capital have an API?
No public API is recorded for Yuuwa Capital.
What industry is Yuuwa Capital in?
Yuuwa Capital's product category is Venture Capital. Its primary akta.pro industry code is FSANAGAF, Emerging Manager / Seeding Platforms (Multi-Manager). Its NAICS code is 523940 and its SIC code is 6282.